Metastases, Neoplasm Clinical Trial
Official title:
Clinical Trial of Intraperitoneal CAR-T Cells Infusion for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis
To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.
Chimeric antigen receptor modified T (CAR-T) cells have the capability in targeting and recognizing tumor antigen, and can specifically recognize, bind and kill tumor cells with positive antigen. Through local drug delivery, CAR-T cells have successfully achieved remarkable effect to treat solid tumors. Gastric cancer is one of the most frequent malignant tumors with high mortality, especially in China. Peritoneal metastasis is one of the common routes of metastasis. Once peritoneal metastasis occurred, patients should be categorized as clinical pathological stage IV with extremely poor prognosis, and the effect of routine treatments would be unsatisfactory. Epithelial cell adhesion molecule (EpCAM) is highly expressed in gastric cancer cells and closely associated with the poor prognosis of patients. In our previous pre-clinical research researches, the investigators have obtained CAR-T cells targeting EpCAM (EpCAM CAR-T), and finished the preparations of cells which could be used in clinical practice. Based on our previous works, the investigators aim to investigate the safety and efficacy of peritoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial. The results of this clinical trial are expected to provide the new treatment strategy for gastric cancer patients with peritoneal metastasis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00065117 -
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
|
Phase 2 | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Terminated |
NCT00048893 -
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00037869 -
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
|
Phase 3 | |
Completed |
NCT02265549 -
Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
|
N/A | |
Completed |
NCT00034918 -
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
Completed |
NCT01115751 -
A Study in Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00056173 -
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05419518 -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
|
Phase 2 | |
Terminated |
NCT00034697 -
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
|
Phase 2 | |
Completed |
NCT00055471 -
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT00046527 -
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT00046514 -
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00041808 -
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
|
Phase 1/Phase 2 | |
Completed |
NCT00037609 -
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00038038 -
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
N/A | |
Completed |
NCT03670992 -
Surgical Treatment of Pancreatic RCC Metastases
|
||
Terminated |
NCT00050336 -
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
|
Phase 3 | |
Completed |
NCT00044863 -
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
|
Phase 2 |